5. Results

Two cDNA libraries, from mouse kidney and human fetal brain tissues, were prepared in an *E. coli* expression vector. Since human fetal brain tissue was more difficult to obtain, the mouse library was prepared first to test the expression system and the detection of expression clones. A vector was chosen for expression of His_6 -tagged fusion proteins in *E. coli* to enable purification by metal affinity chromatography and immunological detection of expression products. Using robot technology, library clones were picked into microtitre plates and arrayed on filters for screening by DNA hybridisation and with antibodies. Bacteria were arrayed on the filters, grown and subsequently lysed at a density of 9,216 or 27,648 clones per filter. Protein expression was induced by transfer of filters onto agar plates supplemented with IPTG.

Using a monoclonal antibody against the N-terminal Arg-Gly-Ser-His₆ (RGSH₆) tag sequence of the expression products (RGS·His antibody), clones expressing stable recombinant polypeptides were selectively recognised on protein filters. A technique was established to go directly from a cDNA probe to an expression clone. High-density DNA filters of the human fetal brain cDNA library were screened with a set of cDNA probes of human genes. Positive clones, that had also been detected by the RGS·His antibody, were regarded as putative expression clones of the genes in question. Protein expression by these clones was confirmed by protein-specific antibodies and SDS-PAGE.

Subsets of library clones in microtitre plates can be rearrayed into new microtitre plates by using a robot that transfers bacteria between microtitre plates. With this technique, putative expression clones, detected by the RGS·His antibody, were combined in a new library. This library is highly enriched in clones expressing their inserts in the correct reading frame.

For the characterisation of putative expression clones arrayed in microtitre plates, standard techniques were adapted to the 96-well microtitre plate format. Growth of bacteria, protein expression and purification by nickel affinity chromatography was performed in 96-well microtitre plates to analyse the expression products of 96 clones from the rearrayed human fetal brain library.

A technique was established to verify the predicted sequence of an expression product by mass spectrometry. Proteins were bound to nickel immobilised on magnetic beads, washed and digested with trypsin. The masses of the tryptic peptides were measured by MALDI mass spectrometry and compared to the masses predicted from the sequence.

5.1 Arrayed cDNA expression libraries

5.1.1 Expression vector pQE30NST

pQE-30 (Qiagen) is a pBR322-based expression vector that carries a phage T5 promoter and two *lac* operators for IPTG-inducible recombinant protein expression. pQE30NST was constructed from pQE-30 by introducing a *Not*I site and T7 and SP6 phage promoters into the multi cloning site (Figure 1, GenBank AF074376). Inserts in pQE30NST can be transcribed *in vitro* in sense direction using SP6 RNA polymerase and in antisense direction using T7 RNA polymerase.

5.1.2 Construction of cDNA libraries

cDNA libraries from adult mouse kidney (mKd1) and human fetal brain (hEx1) tissues were constructed in the pQE30NST vector as a resource for expression clones of mouse and human genes, and to generate arrayed expression libraries for facilitated antibody screening.

RNA was isolated from 1.3 g mouse adult kidney and from two human fetal brains (0.57 g) of menstrual age 14.8 and 15.8 weeks, determined by foot length. The yield was 0.4 mg RNA from 0.57 g human fetal brain ($A_{260}/A_{280} = 1.8$) and 1.8 mg RNA from 1.3 g mouse adult kidney ($A_{260}/A_{280} = 2.0$). Poly(A)⁺ RNA was selected by hybridisation to biotinylated oligo(dT) and immobilisation on streptavidin magnetic beads (Table 1).

cDNA was synthesised by oligo(dT) priming according to Gubler and Hoffman (101). Mouse kidney and human fetal brain poly(A)⁺ RNA was reverse transcribed to generate first strand cDNA (Table 2, Figure 2). A primer with a *Not*I restriction site followed by (T)₁₅ was used, and cDNA was radioactively labelled by incorporation of $[\alpha$ -³²P]dCTP. Second strand cDNA was synthesised and *Sal*I and *Not*I overhangs were generated at the 5' and 3'-ends of the

| tissue | total | wash | wash | wash | eluate before | eluate after |
|-------------|-------|------|------|------|---------------|---------------|
| | RNA | 1 | 2 | 3 | precipitation | precipitation |
| mouse adult | 700 | 5.5 | 2.2 | 0.5 | 8.3 | 5.0 |
| kidney | | | | | | |
| human fetal | 400 | 7.8 | 0.3 | 0.1 | 3.3 | 1.8 |
| brain | | | | | | |

Table 1. RNA amounts in μg during poly(A)⁺ selection.

reverse transcribed mRNA sequences. cDNA was size-fractionated on gel filtration columns (Table 3).

A helper plasmid (pSE111) for over-expression of the LacI repressor was used to maximise repression via the lac operators of the pQE30NST vector. pSE111 additionally contains the argU gene of a rare arginine tRNA which was shown to improve the expression of genes with multiple AGG or AGA arginine codons (92).

Individual size fractions were ligated with the pQE30NST vector, followed by transformation of bacteria carrying the pSE111 helper plasmid. Using a robot, 27,600 clones and 193,500 clones of the mouse kidney (mKd1) and the human fetal brain (hEx1) library, respectively, were picked into 384-well microtitre plates filled with medium (see 4.4.9).

The average size of the cDNA inserts was 1.7 kbp for mKd1 and 1.5 kbp for hEx1, as determined by PCR.



Figure 1. Map of pQE30NST. Unique restriction sites are shown.



Figure 2. Gel electrophoresis of first strand cDNA. (A) Mouse kidney, (B) human fetal brain. Lane 1: size marker; Lane 2: cDNA. Radioactively labelled first strand cDNA was separated by denaturing alkaline agarose gel electrophoresis. Autoradiograms were taken with a phosphor imager (Molecular Dynamics).

| | poly(A) ⁺ | yield first strand | specific activity |
|-------------------|----------------------|--------------------|-------------------|
| | RNA | cDNA | double stranded |
| | | [µg ssDNA] | cDNA [cpm / ng |
| | | | dsDNA] |
| mouse kidney | 2.5 µg | 2.0 | 47.5 |
| human fetal brain | 1.6 µg | 0.83 | 66.4 |

| Fraction | Mouse kidney | Human fetal | | |
|----------|--------------|-----------------|--|--|
| | cDNA [ng] | brain cDNA [ng] | | |
| 1 | <1.0 | <1.0 | | |
| 2 | <1.0 | <1.0 | | |
| 3 | <1.0 | <1.0 | | |
| 4 | <1.0 | <1.0 | | |
| 5 | <1.0 | 1.1 | | |
| 6 | <1.0 | 14 | | |
| 7 | 3.3 | 44 | | |
| 8 | 28 | 90 | | |
| 9 | 94 | 116 | | |
| 10 | 134 | 121 | | |
| 11 | 116 | 115 | | |
| 12 | 102 | 96 | | |

Table 3. cDNA size fractions. Yield of fractions after size fractionation by gel filtration.

5.1.3 Preparation of high-density filters

DNA and protein filters representing clones of the mKd1 and hEx1 libraries at high density were prepared for screening of the libraries by DNA hybridisation or by detection of protein products. Clones were spotted in duplicate at a density of 9,216 or 27,648 per 22.2×22.2 cm². The preparation of DNA filters followed an established procedure (106). For the preparation of protein filters, protein binding PVDF membranes were used, which are more robust and have a higher binding capacity than standard nitro-cellulose filters. Bacterial cultures of arrayed clones were spotted onto the filters by a robot. Following overnight growth of the colonies, the filters were transferred onto agar plates containing IPTG to induce protein expression. Finally bacteria were lysed and proteins were fixed on the filter under denaturing conditions (see 4.5.2).

5.1.4 Screening for recombinant protein expression

To detect clones expressing their inserts as fusion proteins, the RGS·His antibody directed against the N-terminal sequence $RGSH_6$ of these proteins was used. This antibody can be used to discriminate clones that express relatively large fusion proteins from those that express short, and therefore unstable peptides in a colony blot. If a cDNA insert is translated in an incorrect reading frame, the product will usually be short because stop codons are frequent. Therefore, the RGS·His antibody can be used to discriminate between clones that express their cDNA insert in the correct reading frame yielding stable products and clones that express their inserts in incorrect reading frames or that express proteins that are unstable in bacterial cells.

This was tested by screening a protein filter representing 9,216 clones of the mKd1 library with the RGS·His antibody. About 20% of clones showed a signal, varying in intensity (Figure 3). Each clone was spotted in duplicate on the protein filters, thus each clone was represented by a pair of spots. Duplicate spotting is a means of controlling screening results, as only duplicate signals corresponding to the same clone are regarded as true positives. When screening with the RGS·His antibody, pairs of spots corresponding to the same clone generally had similar signal intensities, as expected.

The signals on the protein filter were grouped into intensity levels one (weak) to three (strong). The expression products of twelve clones of each intensity level were analysed by western blotting (Figure 4). Clones expressing proteins of at least 15 kd size were assumed to contain inserts in the correct reading frame, because of the frequency of stop codons of 3 in 64 in non-coding reading frames (see 6.2.2). The percentage of clones expressing proteins of at least 15 kd size was ranging from 83% for intensity level three to 42% for level one.



1 cm





Figure 4: Expression products of clones detected with different intensities by the RGS·His antibody on a high-density protein filter. The expression products of twelve clones from the mouse kidney cDNA library mKd1 detected with intensity 3, 2 and 1 were analysed by western blotting with the RGS·His antibody. M: marker. (•): clones expressing proteins of at least 15 kd size. A band at 45 kd size in lanes 4–12 of the western blot of intensity 1 clones is presumably due to an *E. coli* protein cross-reacting with the RGS·His antibody.

5.2 Rearraying of potential expression clones in the hEx1 library

Potential expression clones detected on high-density protein filters of the hEx1 library were rearrayed into a new library, which is highly enriched in clones expressing their insert in the correct reading frame. When cDNA clones are identified in this sub-library by DNA hybridisation techniques, the protein product could be directly generated. 37,830 of 193,536 clones (384-well microtitre plates 1–504) of the hEx1 library, detected by the RGS·His antibody, were rearrayed by a robot into new microtitre plates, which were labelled as plates 505–604 of hEx1.

High-density protein filters of the original library were prepared in 3×3 (plates 1–210) and 5×5 (plates 1–504) pattern. His₆-tag fusion proteins were detected with the RGS·His antibody. Image analysis software was used that can score positives automatically (see 4.6). Since not all positives were found by this software, positives were also scored manually. Lists of positive clones were generated and used to control a robot which automatically picked the specified clones from the original 'mother' microtitre plates to inoculate cultures in fresh 'daughter' plates. A copy of the rearrayed library was given to RZPD to generate and distribute high-density DNA and protein filters.

5.2.1 Expression and purification in microtitre plates

The rearrayed hEx1 sub-library contains 37,830 clones, of which the RGS-His antibody detected one third of clones with low and two thirds with medium or high signal intensity. The expression products of 96 randomly selected clones of the rearrayed sub-library, detected as medium or high intensity signals, were analysed. Bacteria were grown and protein expression was induced in microtitre plates. The expression products were analysed by SDS-PAGE of whole cellular proteins (Figure 6). Furthermore, His₆-tagged proteins were purified in microtitre plates by using Ni-NTA agarose beads and filter plates, and eluted proteins were analysed by SDS-PAGE (Figure 7).

63 (66%) of the 96 clones expressed proteins of at least 15 kd size visible in SDS-PAGE of whole cellular proteins (Table 4, Table 5). 10% showed expression products of less than 15 kd, and for the remaining 27% of clones, no expression products could be observed. Expression products of 96 clones were subjected to Ni-NTA affinity purification, and protein products larger than 15 kd of 66 clones were nickel affinity purified under denaturing

conditions. Six expression products were purified which could not be detected before in whole cellular protein extracts separated by SDS-PAGE.

5.2.2 Solubility

In order to test the solubility of expressed proteins, cells were lysed with lysozyme and soluble proteins were separated from the insoluble fraction in microtitre plates by centrifugation, followed by filtration with 0.65 μ m pore size microtitre filter plates. By SDS-PAGE, the expression products of 15 of the 63 clones previously identified in whole cellular protein extracts were found to be, at least partially, soluble (Figure 8).

5.2.3 DNA sequence analysis

cDNA inserts were amplified by PCR, and an average insert size of 1.5 kbp was determined. 5'-tag sequences of 93 cDNA inserts were obtained and used to search the combined SWISS-PROT and TrEMBL protein database (113) with the program BLASTX (114). 58 of 93 sequences matched human proteins in this database (Table 4). 38 of these (66%) were fused to the His₆-sequence in the correct reading frame. In 35 of these clones, expression of His₆-tag fusion proteins was observed. The remaining clones had been detected by the RGS·His antibody despite the fact that the fusion with the protein coding sequence with the His₆-tag was out of frame. The expression products of clones with insert in an incorrect reading frame were generally smaller than of clones with inserts in the correct reading frame, as shown in Figure 5.

38 (66%) of the 58 known coding sequences matched to the beginning of a human protein sequence, suggesting that the complete coding region had been cloned (full length clones). As expected, full-length sequences matched smaller protein sequences in the database (average 35 kd) than sequences lacking the N-terminus (average 61 kd).

The expression products and insert sequences of 96 clones from the rearrayed hEx1 sublibrary were analysed. SDS-PAGE analysis of whole cellular proteins had shown that two thirds of these clones express proteins of at least 15 kd size. 57 clones had inserts matching human protein sequences in databases. 66% of these had inserts in the correct reading frame and nearly all of them were translated as proteins with the predicted size as determined by SDS-PAGE. 66% of clones with inserts in the correct reading frame contained the complete



reading frame (full length clones). About 25% of expression products appeared at least partially soluble.

Figure 5. Size Distribution of expressed proteins. The distribution of size estimated by SDS-PAGE of proteins expressed in clones containing inserts in the correct (grey) and incorrect (black) reading frame.



Figure 6. Whole cellular proteins. The lanes are labelled with clone names without the suffix MPMGp800. E.g. the first clone in the first gel is MPMGp800A02582. Controls were included in the 96-well plate. C1: GAPDH, C2: non-expressing clone, C3: sterility control. SDS-PAGE followed by Coomassie blue staining.

| M M 04582 C04582 F0045582 F0045585 F00455585 F00455585 F00455585 F00455585 F00455585 F0045555 F0045555 F0045555 F0045555 F0045555 F0045555 F0045555 F00455555 F00455555 F00455555 F00455555 F00455555 F00455555 F00455555 F004555555 F0045555555 F0045555555 F0045555555555 | W A06582 C06582 C08582 C08582 E08582 E08582 E08582 C08582 K06582 K06582 K06582 M06582 M06582 008582 008582 008582 008582 |
|--|--|
| 66.2 39.2 26.6 | |
| 21.5 | |
| ₩ A10582 A10582 C10582 E10582 E12582 G10582 G10582 C12582 T12582 C10582 M10582 M12582 M12582 010582 010582 012582 | W A14582 A14582 C14582 C14582 C14582 E14582 G14582 G14582 C14582 M14582 M14582 M14582 N14582 014582 014582 014582 016582 |
| 97.4 66.2 39.2 26.6 | |
| 21.5 | • |
| A18582 A18582 C18582 C18582 C18582 C18582 G18582 G18582 G18582 G18582 C20582 T18582 K20582 K20582 M20582 M20582 M20582 O18582 O20582 O2 | W A24582 A24582 C22582 C22582 E24582 E24582 C24582 C24582 C24582 C24582 K24582 C22582 K24582 N22582 M24582 N22582 N22582 C2582 C2582 C2582 C2582 C2582 C2582 C2582 C2582 C |
| 66.2 39.2 26.6 | |
| 14.4 | |
| | |

Figure 7. Ni-NTA purification. The lanes are labelled as in Figure 6. Controls were included. C1: GAPDH, C2: non-expressing clone. C4: clone expressing part of HSP90α. SDS-PAGE followed by Coomassie blue staining of Ni-NTA purified proteins.



Figure 8. Soluble proteins. The lanes are labelled as in Figure 6. (•) Clones expressing soluble recombinant protein. SDS-PAGE followed by Coomassie blue staining.

| | Database match | | | | | | | |
|-------------------|--|--|--|---|---|-----------------------------------|---|---|
| Clone MPMGp800 | Swiss- Prot/ TrEMBL Accession Number | Protein description | Nucleotides in clone sequence that match ^a | Matched amino acids in database sequence | Percent identity (amino acids) | Fused in frame ^b | Expressed protein size in kd [°] | Predicted protein size in dalton |
| A06582 | O00217 | NADH-UBIQUINONE OXIDOREDUCTASE 23 KD SUBUNIT PRECURSOR (EC 1653) | 13–513 | 1–167 | 99 | no | 12 | |
| A08582 | P04687 | TUBULIN ALPHA-1 CHAIN | 3–284 | 174–267 | 100 | yes | 35 | 33859 |
| A12582 | P04765 | EUKARYOTIC INITIATION FACTOR 4A-I (EIF-4A-I) | 3–260 | 12–97 | 97 | yes | 50 | 47808 |
| A14582 | Q11203 | CMP-N-ACETYLNEURAMINATE-B- 1,4-GALACTOSIDE ALPHA-2,3- SIALYLTRANSFERASE (EC 24996) | 3–203 | 234–300 | 97 | yes | 20 | 18825 |
| A16582 | P13639 | ELONGATION FACTOR 2 (EF-2) | 84–299 | 1–72 | 100 | yes | 97 | 98098 |
| A18582 | P49006 | MARCKS-RELATED PROTEIN (MAC- MARCKS) | 188–262 | 1–25 | 80 | no | | |
| A20582 | P56182 | NNP-1 PROTEIN (D21S2056E) | 3-209 | 240-308 | 100 | yes | 34 | 27850 |
| A24582 | P49006 | MARCKS-RELATED PROTEIN (MAC- MARCKS) | 200–310 | 1–37 | 95 | no | 12 | |
| C06582 | Q15853 | UPSTREAM STIMULATORY FACTOR 2 | 16–294 | 128–220 | 95 | no | 18 | |
| C10582 | P36578 | 60S RIBOSOMAL PROTEIN L1 (L4) | 43-240 | 1–66 | 92 | no | 10 | |
| C12582 | P49006 | MARCKS-RELATED PROTEIN (MAC- MARCKS) | 175–417 | 1-81 | 96 | no | 16 | |
| E02582 | P43308 | TRANSLOCON-ASSOCIATED PROTEIN, BETA SUBUNIT PRECURSOR (TRAP-BETA) | 43–237 | 1–65 | 97 | no | 10 | |
| E04582 | P14793 | 60S RIBOSOMAL PROTEIN L40 (CEP52) | 11–61 | 36–52 | 94 | no | 10 | |
| E12582 | P25111 | 40S RIBOSOMAL PROTEIN S25 | 47–196 | 1–50 | 94 | no | 10 | 1 |
| E14582 | P04687 | TUBULIN ALPHA-1 CHAIN | 2-190 | 304–366 | 98 | no | 23 | 1 |
| E18582 | Q15560 | TRANSCRIPTION ELONGATION FACTOR S-II, HS-II-T1 | 96–167 | 1–24 | 92 | yes | 10 | 39239 |
| E20582 | Q13885 | BETA TUBULIN | 3–230 | 275-350 | 90 | yes | 27 | 19747 |
| G02582 | P14923 | JUNCTION PLAKOGLOBIN | 3-314 | 287-390 | 98 | yes | 50 | 53034 |

 Table 4. Database matches and Protein expression.

| | Database match | | | | | | | |
|-------------------|--|---|--|---|---|-----------------------------------|---|---|
| Clone MPMGp800 | Swiss- Prot/ TrEMBL Accession Number | Protein description | Nucleotides in clone sequence that match ^a | Matched amino acids in database sequence | Percent identity (amino acids) | Fused in frame ^b | Expressed protein size in kd ^c | Predicted protein size in dalton |
| G04582 | 016478 | GLUTAMATE RECEPTOR SUBUNIT | 11–193 | 832-892 | 100 | no | | |
| G10582 | P07108 | ACYL-COA-BINDING PROTEIN (ACBP) | 69–323 | 1-85 | 95 | yes | 15 | 15098 |
| G12582 | P48735 | ISOCITRATE DEHYDROGENASE (NADP), MITOCHONDRIAL PRECURSOR (EC 11142) | 60–230 | 1–57 | 98 | yes | 50 | 55802 |
| G14582 | P39023 | 60S RIBOSOMAL PROTÉIN L3 | 1–282 | 225-318 | 92 | no | 10 | |
| G16582 | P15880 | 40S RIBOSOMAL PROTEIN S2 (S4) (LLREP3 PROTEIN) | 6–218 | 1–71 | 92 | yes | 35 | 34328 |
| G20582 | P54198 | HIRA PROTEIN | 3–314 | 383–486 | 99 | yes | 65 | 72278 |
| 102582 | P36404 | ADP-RIBOSYLATION FACTOR-LIKE PROTEIN 2 | 40–255 | 1–72 | 96 | no | | |
| I04582 | P30086 | PHOSPHATIDYLETHANOLAMINE- BINDING PROTEIN | 99–233 | 1–45 | 100 | yes | 29 | 27046 |
| I06582 | P25111 | 40S RIBOSOMAL PROTEIN S25 | 36-254 | 1–73 | 100 | yes | 23 | 17678 |
| I10582 | P39023 | 60S RIBOSOMAL PROTEIN L3 | 9–215 | 1–69 | 99 | yes | 50 | 49026 |
| I12582 | P15880 | 40S RIBOSOMAL PROTEIN S2 (S4) (LLREP3 PROTEIN) | 6–170 | 1–55 | 96 | yes | 35 | 34328 |
| I14582 | Q13098 | G PROTEIN PATHWAY SUPPRESSOR 1 (GPS1 PROTEIN) | 2–250 | 193–275 | 98 | no | 18 | |
| I18582 | P05092 | PEPTIDYL-PROLYL CIS-TRANS ISOMERASE A (EC 5218) | 21–206 | 1–62 | 100 | yes | 22 | 21441 |
| 120582 | P02570 | ACTIN, CYTOPLASMIC 1 (BETA- ACTIN) | 78–146 | 1–23 | 100 | yes | 45 | 47297 |
| I24582 | P23396 | 40S RIBOSOMAL PROTEIN S3 | 12-200 | 1–63 | 98 | yes | 32 | 29749 |
| K04582 | Q03827 | TRANSCRIPTION FACTOR ETR101 | 3–383 | 97–223 | 98 | yes | | 16184 |
| K08582 | Q00403 | TRANSCRIPTION INITIATION FACTOR IIB (TFIIB) | 18–296 | 1–93 | 100 | yes | 38 | 38133 |
| K10582 | O15143 | ARP2/3 COMPLEX 41 KD SUBUNIT (P41-ARC) | 81–400 | 1–68 | 93 | yes | 45 | 46403 |
| K12582 | Q15666 | ASPARAGINE SYNTHETASE (FRAGMENT) | 376–513 | 1-46 | 100 | no | 21 | |
| K14582 | P49241 | 40S RIBOSOMAL PROTEIN S3A | 15-209 | 1–65 | 100 | yes | 35 | 33094 |

| | Database match | | | | | | | |
|-------------------|--|--|--|---|---|-----------------------------------|---|---|
| Clone MPMGp800 | Swiss- Prot/ TrEMBL Accession Number | Protein description | Nucleotides in clone sequence that match ^a | Matched amino acids in database sequence | Percent identity (amino acids) | Fused in frame ^b | Expressed protein size in kd ^c | Predicted protein size in dalton |
| K16582 | Q99719 | CELL DIVISION CONTROL RELATED PROTEIN | 101–505 | 1–135 | 97 | no | | |
| K18582 | P04687 | TUBULIN ALPHA-1 CHAIN | 3–182 | 306-366 | 93 | yes | 21 | 16282 |
| K20582 | O00240 | DIHYDROPYRIMIDINASE RELATED PROTEIN-4 (DRP-4) | 94–471 | 1–126 | 99 | no | 14 | |
| M02582 | Q13885 | BETA TUBULIN | 1–243 | 253–333 | 98 | no | 27 | |
| M04582 | P49368 | T-COMPLEX PROTEIN 1, GAMMA SUBUNIT (TCP-1-GAMMA) | 6–249 | 19–99 | 100 | yes | 60 | 61326 |
| M10582 | P02571 | ACTIN, CYTOPLASMIC 2 (GAMMA- ACTIN) | 60–209 | 1–50 | 92 | yes | 45 | 46718 |
| M12582 | P32969 | 60S RIBOSOMAL PROTEIN L9 | 7–201 | 1–65 | 89 | no | 14 | |
| M18582 | Q13885 | BETA TUBULIN | 51-281 | 1–77 | 99 | yes | 58 | 54291 |
| M20582 | P02768 | SERUM ALBUMIN PRECURSOR | 3–233 | 116–192 | 100 | yes | 60 | 59076 |
| M22582 | P02570 | ACTIN, CYTOPLASMIC 1 (BETA- ACTIN) | 78–209 | 1–44 | 93 | yes | 45 | 47297 |
| M24582 | Q06830 | THIOREDOXIN PEROXIDASE 2 | 42-227 | 1–62 | 98 | yes | 25 | 26231 |
| O02582 | Q02878 | 60S RIBOSOMAL PROTEIN L6 | 3–257 | 1-85 | 100 | yes | | 35457 |
| O04582 | Q02878 | 60S RIBOSOMAL PROTEIN L6 | 3–290 | 1–96 | 92 | yes | | 35457 |
| O06582 | P17080 | GTP-BINDING NUCLEAR PROTEIN RAN (TC4) | 45–335 | 1–97 | 99 | yes | 30 | 28494 |
| O08582 | Q08379 | GOLGIN-95 | 3–239 | 414–492 | 96 | yes | 30 | 26312 |
| O10582 | P01922 | HEMOGLOBIN ALPHA CHAIN | 39–200 | 1–62 | 96 | yes | 20 | 15126 |
| O14582 | P21810 | BONE/CARTILAGE PROTEOGLYCAN I PRECURSOR (BIGLYCAN) (PG-S1) | 131–202 | 1–24 | 100 | no | | |
| O16582 | Q15597 | TRANSLATION INITIATIONFACTOR EIF-4GAMMA (FRAGMENT) | 15–245 | 215–291 | 100 | yes | 60 | 58069 |
| 018582 | Q14257 | CALCIUM-BINDING PROTEIN ERC- 55 PRECURSOR | 147–506 | 24–143 | 99 | yes | 60 | 42157 |
| O20582 | Q02543 | 60S RIBOSOMAL PROTEIN L18A | 27–242 | 1–72 | 97 | yes | 26 | 24374 |

^a Nucleotides counted from the beginning of the 5'-end of the insert sequence. ^b Protein coding sequence fused to His₆-tag in frame ^c Estimated by SDS-PAGE. Empty field: no expression was observed.

| Clone | expressed | | |
|----------|---------------|--|--|
| MPMGp800 | protein, size | | |
| - | in kd | | |
| A02582 | 60 | | |
| A04582 | 23 | | |
| A10582 | 26 | | |
| A22582 | | | |
| C02582 | 10 | | |
| C04582 | 38 | | |
| C08582 | 35 | | |
| C14582 | | | |
| C16582 | 35 | | |
| C18582 | 55 | | |
| C20582 | 8 | | |
| C22582 | 35 | | |
| C24582 | 18 | | |
| E06582 | 16 | | |
| E08582 | 22 | | |
| E10582 | 55 | | |
| E16582 | 22 | | |
| E22582 | 21 | | |
| E24582 | 37 | | |
| G06582 | 15 | | |
| G08582 | 22 | | |
| G18582 | | | |
| G22582 | 55 | | |
| G24582 | 22 | | |
| I08582 | 20 | | |
| I16582 | 12 | | |
| I22582 | 40 | | |
| K02582 | 10 | | |
| K06582 | 35 | | |
| K22582 | | | |
| K24582 | | | |
| M06582 | 75 | | |
| M08582 | 8 | | |
| M14582 | 45 | | |
| M16582 | 30 | | |
| O12582 | 15 | | |
| O22582 | 23 | | |
| O24582 | 30 | | |

Table 5. Protein expression of clones without protein sequence database match. Empty fields indicate no protein expression.

5.3 Identification of expression clones for specific genes

5.3.1 Screening of the hEx1 library with DNA probes

The hEx1 human fetal brain expression library was screened with DNA probes to obtain expression clones for specific genes. Three high-density filters of the original hEx1 library (before rearraying), representing 80,640 clones, were screened with cDNA probes of nine human genes (Table 6, Table 7). A set of genes was chosen that comprises genes of different size and expression strength, and includes cytosolic and transmembrane proteins.

| gene | Probe |
|------------|--|
| BMP-7 | IMAGE (ref. 115) clone 581604 (GenBank W73473, W73527) |
| calmodulin | clone 102J24 containing calmodulin (GenBank D45887) ^a |
| COX4 | clone 159A23 containing COX4 (GenBank M34600) ^a |
| GAPDH | clone 68H22 containing GAPDH (GenBank M33197) ^a |
| hMSH2 | IMAGE clone 283409 (GenBank N50630) |
| HSP90a | IMAGE clone 343722 (GenBank W69361) |
| HSP90β | clone 200A20 containing HSP90β (GenBank M16660) ^a |
| RXRβ | clone containing RXRβ (GenBank X63522) ^b |
| VDAC1 | clone 39E15 containing VDAC1 (GenBank L06132) ^a |

Table 6. cDNA hybridisation probes.

^aobtained from Sebastian Meier-Ewert

^bobtained from Wilfried Nietfeld

The results of the DNA hybridisations were compared with RGS·His antibody screenings of protein filters representing the same clones. Clones positive for both the antibody and a DNA probe were selected for DNA sequencing and analysis of expression products. The results are summarised in Table 7. For seven out of nine genes, expression clones were obtained by this strategy. No expression clones were obtained for bone morphogenetic protein 7 (BMP-7) and voltage-dependent anion channel isoform 1 (VDAC1). For the probe of BMP-7, which belongs to the TGF- β (transforming growth factor β) supergene family, two clones detected by DNA hybridisation were positive with the RGS·His antibody. One clone contained only a part of the 3'-uncoding region of this gene, while the other clone was chimerical and contained

57

an unrelated sequence before the BMP-7 cDNA sequence. None of the positives of VDAC1 were detected by the RGS·His antibody.

For seven genes, expression clones were obtained which expressed the whole or part of the encoded human protein as a His₆-tag fusion protein. Protein sizes predicted from DNA sequences matched sizes estimated from SDS-PAGE. For calmodulin, glyceraldehyde-3phosphate dehydrogenase (GAPDH) and heat shock protein HSP90^β, clones expressing fusions of complete human protein sequences were found. Expression of the HSP90^β full length protein was much weaker than of N-terminal parts of this protein. Expression strength and solubility of expression products generally decreased with increasing HSP90 insert size in different clones (data not shown). Expression of retinoic acid X receptor β (RXR β) was only observed in one clone, but was weak and could only be detected on a western blot. For all other clones, relatively strong expression was observed and recombinant proteins were visible as extra bands of the expected size when separating whole cellular proteins by SDS-PAGE. Fusion proteins of GAPDH, calmodulin and parts of HSP90a (amino acids 190-732) and HSP90ß (amino acids 475–724) were found in the soluble protein fraction. Inclusion bodies of a larger HSP90 β fusion protein (amino acids 42–724) and a cytochrome c oxidase subunit IV (COX4, amino acids 6–169) fusion protein were solubilised with sarkosyl (see 4.10.2). After Ni-NTA purification, HSP90^β was soluble without detergents, while the transmembrane protein COX4 was soluble in 1% TritonX-100. The hMSH2 fusion protein appeared to form inclusion bodies, and was therefore purified under denaturing conditions (data not shown). Figure 9 shows HSP90a, HSP90b, CaM, COX4 and GAPDH fusion proteins purified under native conditions (see 4.10.2). Additional bands in the HSP90 preparations are presumably due to degradation of these proteins during their expression, as similar bands were observed in western blots and upon purification under denaturing conditions.

5.3.2 Biological activity of GAPDH and calmodulin

Biological activity of GAPDH and calmodulin fusion proteins was examined by enzyme assays. This showed that clones expressing functional proteins could be identified in the hEx1 library.

GAPDH

GAPDH catalyses the reaction:

```
D-glyceraldehyde 3-phosphate + NAD^+ + P_i = 1,3-diphosphoglycerate + NADH
```

In the assay for GAPDH (110), 1,3-diphosphoglycerate is produced by the ATP-dependent phosphorylation of D-glycerate 3-phosphate catalysed by phosphoglycerate kinase:

```
1,3-diphosphateglycerate + ADP = D-Glycerate 3-phosphate + ATP
```

One unit is defined as the amount of enzyme that catalyses the reduction of 1 μ mole to 1,3diphosphateglycerate to D-Glyceraldehyde 3-phosphate per minute.

For the GAPDH fusion protein expressed by clone MPMGp800D215, an activity of 40 units/mg was measured, which is somewhat less than the activity of 67 units/mg reported by Heinz and Freimüller (110) for GAPDH from human liver.

Calmodulin

Calmodulin binds Ca^{2+} ions and activates a class of 3',5'-cyclic nucleotide phosphodiesterases (PDE), when Ca^{2+} is present. The biological activity of the calmodulin fusion protein expressed by clone MPMGp800B1273 was measured using a calmodulin-dependent 3',5'-cyclic nucleotide PDE purchased in the activator deficient form (Sigma). This enzyme had an activity of 28 units/mg when activated by calmodulin, and 4.8 units/mg without activator (1 unit hydrolyses 1 µmole cAMP to AMP per minute).

In an assay containing 1.0 mU of PDE without activator, the addition of 3.2 μ g of the calmodulin fusion protein increased the PDE activity to 8.0 mU. The measured 8-fold increase of activity is higher than the 5.8-fold increase reported by the manufacturer of the PDE preparation. (The activity of the PDE preparation may change upon storage.)

 Ca^{2+} -dependence of activation by calmodulin was demonstrated by addition of EGTA to the assay, which reduced PDE activity to the same level as observed without calmodulin. Addition of a surplus of Ca^{2+} restored the activating effect of the calmodulin fusion protein.

In an assay containing 8 mU PDE, 32 ng of the calmodulin fusion protein resulted in 3.0 units, which is approximately 30% of the maximal activating effect. The specific activity of PDE was indicated as 28 units/mg. Mammalian calmodulin dependent PDE have a molecular weight around 62 kd, therefore the assay contained roughly 4.6 pmole PDE. 32 ng of the calmodulin fusion protein, which is 21.5 kd, equals 1.5 pmole. This accounts for the activating effect of approximately 30%, assuming a 1:1-molar complex of calmodulin and PDE.

In summary, the hEx1 library was screened with probes of nine human genes. It was shown, that expression clones are rapidly obtained by this approach. For two genes no expression clones were obtained. One of these, VDAC-1, a membrane protein, may not be expressible in *E. coli*, while the other BMP-7 precursor, represented a rather rare transcript, as only 3 positives were obtained. For RXR β , only one clone was identified which expressed protein only weakly. Enzyme assays of GAPDH and calmodulin fusion proteins expressed by clones in the library demonstrated biological activity.



Figure 9. Purification by metal affinity chromatography of HSP90 α , HSP90 β , calmodulin, COX4 and GAPDH protein. Proteins were separated on 15% SDS-PAGE and stained with Coomassie blue.

| human gene | | Swiss-Prot | DNA | RGS·His | Protein | expressed aa | soluble |
|------------|--|---------------------|------------------------|-----------|-----------------------------------|-----------------------------------|--------------------|
| | | accession number | positives ^a | positives | expression clones ^b | by clone MPMGp800 ^c | |
| BMP-7 | bone morphogenetic protein 7 precursor | P18075 | 3 | 2 | 0 of 2 tested | | |
| CaM | Calmodulin | P02593 | 97 | 21 | 12 of 12 tested | 1–148 B1273 | yes |
| COX4 | cytochrome c oxidase subunit IV | P13073 | 23 | 5 | 2 of 5 tested | 6–169 N0383 | yes ^{d,e} |
| GAPDH | glyceraldehyde-3- phosphate dehydrogenase, liver | P04406 | 207 | 56 | 34 of 56 tested | 1–334 …D215 | yes |
| hMSH2 | DNA mismatch repair protein MSH2 | P43246 | 3 | 1 | 1 of 1 tested | 516–934 P14109 | no |
| HSP90a | heat shock protein 90- α | P07900 | 56 | 14 | 10 of 14 tested | 190–731 G2466 | yes |
| HSP90β | heat shock protein 90- β | P08238 | 87 | 20 | 6 of 8 tested | 42–723 N0360 | yes ^e |
| RXRβ | retinoic acid receptor RXR-β | P28702 | 16 | 4 | 1 of 4 tested | 174–533 D1246 | n.d. |
| VDAC1 | voltage-dependent anion channel isoform 1 | P21796 | 6 | 0 | | | |

Table 7. Screening for protein expression clones and analysis of expressed proteins.

^a Number of positives in DNA hybridisation in 80,640 clones ^b Clones that express human protein with predicted size. ^c e.g. clone MPMGp800B1273 expresses amino acids 1–148 of the Swiss-Prot calmodulin sequence P02593. ^d soluble in 1% TritonX-100

^e inclusion bodies solubilised in sarkosyl

n.d.: not determined

5.3.3 Detection of GAPDH and HSP90 α expression clones with antibodies and DNA probes

Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Swiss-Prot P04406) and the human heat shock protein HSP90 α (Swiss-Prot P07900) were chosen as examples to demonstrate the detection of expression clones by the RGS·His antibody. These two proteins were chosen, because they differ in size and expression strength, and antibodies against both proteins were available. DNA hybridisation screenings of the hEx1 library with DNA probes of GAPDH and HSP90 α , in combination with the RGS·His antibody screening of the library, identified a number of putative expression clones (see 5.2). Antibodies against GAPDH and HSP90 α were used to screen high-density protein filters of the library to confirm expression of these proteins.

A set of three DNA filters representing 80,640 clones was screened with DNA probes of GAPDH and HSP90 α (Figure 10, A, C). 237 (0.29%) clones were positive with a human GAPDH probe and 56 (0.07%) clones were identified with a human HSP90 α probe. A subset of about 25% of GAPDH and HSP90 α clones were also positive with the RGS·His antibody on protein filters, and were therefore regarded as putative protein expression clones. In order to confirm the expression of GAPDH or HSP90 α proteins by these clones, high-density protein filters were also screened with antibodies against GAPDH and HSP90 α (Figure 10, B, D; the GAPDH antibody was first used to screen the hEx1 library by D. Cahill). The subsets of GAPDH and HSP90 α clones identified by those protein-specific antibodies and the subsets detected by the RGS·His antibody were not identical but largely overlapping, as shown in the Venn diagram in Figure 11. Most of the potential expression clones detected by the RGS·His antibody were confirmed by the GAPDH and HSP90 α antibodies, indicating that the RGS·His antibody can be used to select expression clones among positives obtained in a DNA hybridisation screening.

In detail, 61% of the GAPDH and 72% of the HSP90 α clones detected by the RGS·His antibody were also positive with the protein-specific antibodies (category A in Figure 11). It was shown by sequencing that the remaining clones (category B) had inserts in an incorrect reading frame, even though they were detected by the RGS·His antibody. Furthermore, two

clones expressed C-terminal parts of GAPDH, which were detected only poorly by the GAPDH antibody in a western blot (Figure 12, lane 11, 12).

In turn, 100% of the anti-GAPDH but only 35% of the anti-HSP90 α positive clones were detected by the RGS·His antibody. This indicated HSP90 α molecules without a His₆-tag. Sequence analysis showed that all of those RGS·His-negative HSP90 α clones had inserts in incorrect reading frames. They nevertheless expressed proteins that were detected by the HSP90 α antibody in western blots, but not by the RGS·His antibody (Figure 13 E).

The aim of screening the hEx1 library with DNA probes and antibodies for GAPDH and HSP90 α was to differentiate between expression and non-expression clones. Ideally, among clones detected by GAPDH and HSP90 α DNA probes, expression clones would be recognised by antibodies against GAPDH or HSP90 α and the RGS·His antibody, while non-expression would not be recognised by any antibody. Thus, expression clones would be found in category A and non-expression clones would be found in category C of the Venn diagram in Figure 11. In reality, several clones were detected only by the RGS·His antibody (category B) or only by a protein-specific antibody (category E), and not by both antibodies. Clones detected by different combinations of DNA probes and antibodies, as represented by the categories A–E in Figure 11, were analysed by SDS-PAGE, western blotting (Figure 12, Figure 13) and DNA sequencing (Figure 14).

A. Clones identified by a DNA probe, the GAPDH or HSP90 α antibody and the RGS·His antibody

These clones expressed GADPH or HSP90 α fusion proteins, and were detected by a specific antibody and the RGS·His antibody.

Ten GAPDH clones identified with the DNA probe, the GAPDH and the RGS-His antibody were sequenced and found to contain GAPDH sequences in the correct reading frame. They expressed recombinant His₆-tagged fusion proteins of the GAPDH coding sequence, part of the 5'-untranslated region and vector-encoded amino acids (Figure 12 A). Nine clones comprised the full GAPDH coding sequence.

All ten clones positive with the HSP90 α DNA probe, the RGS·His and the HSP90 α antibody contained HSP90 α sequences in the correct reading frame. None of them accommodated the full coding region. The expression products of five clones were analysed by SDS-PAGE and

western blotting with HSP90 α and RGS·His antibody (Figure 13 A). Their estimated molecular weights corresponded to those predicted from the DNA sequences.

B. Clones identified by a DNA probe and the RGS·His antibody, not by the protein specific antibodies

Most clones in this category contained inserts in an incorrect reading frame and were therefore not detected by protein-specific antibodies.

Sequences of seven GAPDH clones negative with the specific antibody on filters were shown to overlap the GAPDH GenBank sequence. Two of these clones had inserts in the correct reading frame and expressed C-terminal GAPDH fragments (24 kd) poorly recognised by the GAPDH antibody on western blots (Figure 12 B, lanes 11, 12). GAPDH inserts were in incorrect reading frames in the other five clones. DNA sequence analysis predicted that these clones expressed polypeptides of 6.5–16.7 kd size from incorrect reading frames of GAPDH inserts. Such polypepetides were not or only weakly detected on a RGS·His western blot (Figure 12 B, lanes 13–17). Signal intensities of these clones were generally low when probed with RGS·His on high-density filters.

Three of four HSP90 α clones had inserts in an incorrect reading frame, expressing short peptides not reactive with the HSP90 α antibody (two clones shown in Figure 13, lanes 6, 8). The remaining clone carried an insert in the correct reading frame, gave a band of the calculated size (56.0 kd) on western blots (Figure 13, lane 7) and was detected by the HSP90 α antibody in a second high-density filter screening.

C. Clones identified only by a DNA probe

This category comprises clones with inserts translated in a incorrect reading frame, that did not express GADPH or HSP90 α fusion proteins, and were therefore not detected by protein-specific antibodies and the RGS-His antibody.

Eleven of twelve randomly selected GAPDH clones contained a GAPDH insert in an incorrect reading frame, supposedly expressing peptides in the range of 3.4 to 9.1 kd. Clone MPMGp800A1755 had an insert in the correct reading frame but carried a point mutation at position -8 in the 5'-untranslated region, leading to a stop codon.

Eleven of twelve HSP90 α clones contained inserts in an incorrect reading frame and were predicted to express peptides of 2.8–5.4 kd calculated molecular mass. Only clone

MPMGp800I13115 had an insert in the correct reading frame, expressed a protein of 78.7 kd size (data not shown) and was positive in a second HSP90α antibody screening.

D. Clones identified by the HSP90 α and the RGS·His antibodies, not by the HSP90 α DNA probe

All four clones in this category expressed polypeptides detected on western blots (Figure 13D). Clone MPMGp800G06207 (lane 12) contained an HSP90a insert with a 46 bp deletion and was obviously a false negative for the HSP90a DNA probe. Three clones, two of them were identical, were recognised by the HSP90a antibody but not in a DNA hybridisation with the HSP90a DNA probe. These clones did not contain HSP90a sequences, suggesting cross-reactivity of the HSP90a antibody. Binding of the HSP90a antibody was confirmed in a western blot (Figure 13, lanes 9–11). The DNA sequences of these three clones comprising the full translated open reading frames in these clones matched sequences of anonymous cDNA clones (ESTs) in database searches. No common motifs of significant homology were found by comparison of the expressed protein sequences and the HSP90a sequence with the program BESTFIT (Wisconsin Package Version 9.1, Genetics Computer Group, Madison).

E. Clones identified by the HSP90 α DNA probe and antibody, not by the RGS·His antibody

Clones in this category contained inserts in a incorrect reading frame, but nevertheless expressed proteins detectable by the HSP90 α antibody. Ten clones recognised by the HSP90 α DNA probe and the HSP90 α antibody but not by the RGS·His antibody, were found to contain HSP90 α sequences inserted in an incorrect reading frame. His₆-tagged polypeptides expressed from these clones would have calculated masses of 3.2–6.1 kd and were not found in western blots (Figure 13 E). In contrast, bands were observed with the HSP90 α antibody suggesting translational start sites within the HSP90 α inserts.

Table 8. Numbers of identified clones. See legend of Figure 11 for explanation of the categories A–E.

| category | GAPDH | HSP90a |
|----------|-------|--------|
| А | 37 | 10 |
| В | 23 | 4 |
| С | 177 | 24 |
| D | 0 | 4 |
| E | 0 | 18 |
| total | 237 | 60 |



Figure 10. Identification of GAPDH and HSP90 α expression clones in the hEx1 library. (A) Screening of a DNA filter representing 27,648 cDNA clones with a GAPDH-specific DNA probe. (B) Screening of an identical protein filter with GAPDH antibody. (C) Screening with a HSP90 α DNA probe and (D) a monoclonal HSP90 α antibody. Corresponding sections of filters are shown. Filters were spotted in a 5×5 pattern indicated in (B).



Figure 11. Categories of clones identified by DNA probes and antibodies. Circles represent sets of clones detected with individual probes. The large segments of circles represent all clones that were detected by the RGS·His antibody in the library. Clones in intersections labelled A,B,D,E were detected by multiple probes. A: detected by RGS·His and specific antibody, and DNA probe; B: detected by RGS·His antibody and DNA probe, not by specific antibody; C: detected by DNA probe only; D: detected by RGS·His and specific antibody; E: detected by specific antibody and DNA probe.



Figure 12. Protein products of clones detected by RGS·His and/or GAPDH antibody.

Shading and numbers in boxes across the top indicate signal intensities on high-density filters. The letters A and B refer to the categories in Figure 11. GAPDH and RGS·His antibody western blots and Coomassie blue stained SDS-PAGE of whole cellular proteins are shown.



Figure 13. Expression products of clones detected by RGS·His and/or HSP90 α antibody. Shading and numbers in boxes across the top indicate signal intensities on high-density filters. The letters A–E refer to the categories in Figure 11. HSP90 α and RGS·His antibody western blots and Coomassie blue stained SDS-PAGE of whole cellular proteins are shown.

GAPDH clones

GAPDH mRNA MPMGp800G1510 MPMGp800K1523 MPMGp80011028 MPMGp800G1940 MPMGp800H0647 А MPMGp800L1347 MPMGp800F1959 MPMGp800J1767 MPMGp800K1570 MPMGp800D215 MPMGp800C0535 MPMGp800H0960 MPMGp800E077 MPMGp80011710 В MPMGp800C0643 MPMGp800H1852 MPMGp800M1052 MPMGp800A1755 MPMGp800B1972 MPMGp800C2166 MPMGp800D0555 MPMGp800F0963 MPMGp800G1463 MPMGp80011755 С MPMGp800K0150 MPMGp800L1567 MPMGp800M0869 MPMGp800M1571 MPMGp800P1953 MPMGp800H0978 D MPMGp800J2284 MPMGP800K2177 MPMGp800M1292 bp 25 500 75 1000 1250 HSP90 α clones HSP90α mRNA MPMGp800P1091 MPMGp800H19113 MPMGp800D09156 MPMGp800P06166 MPMGp800N15170 А MPMGp800A1523 MPMGp800L0155 MPMGp800G2466 MPMGp800M1470 MPMGp800014140 MPMGp800B13169 В MPMGp800I10169 MPMGp800J2361 MPMGp800A0353 MPMGp80012258 MPMGp800N2182 MPMGp800P1093 MPMGp800I1496 MPMGp800I15107 С MPMGp800I13115 MPMGp800B20151 MPMGp800F02164 MPMGp800E22169 MPMGp800K04157 D^{-} MPMGp800G06207 MPMGp800N1273 MPMGp800F20109 MPMGp800J16139 MPMGp800F03153 MPMGp800C24156 MPMGp800N08162 Ε MPMGp800005169 MPMGp800F20194 MPMGp800K10198 MPMGp800L11206

Figure 14. Sequence alignments of GAPDH and HSP90 α clones. Open reading frames of GAPDH and HSP90 α are shown as open boxes. Each line indicates the length of the sequence expected in the respective clone, with thicker sections showing the fragment actually sequenced and aligned to the full-length mRNA sequence. The letters A–E refer to categories in Figure 11. The shaded part of HSP90 α represents the peptide that was used to generate the anti-HSP90 α antibody.

1000

1250

1500

1750

2000

2250

2500

2750 bp

250

500

750

5.4 Characterisation of expression products by mass spectrometry

With mass spectrometry using matrix assisted laser desorption/ionisation (MALDI-MS) and time-of-flight (TOF) measurement, the molecular mass of proteins or peptides can be determined with high accuracy. A procedure for direct measurement of expression products from bacterial clones by MALDI-MS was established. Bacteria were grown in microtitre plates and protein expression was induced. After cell lysis, the expression products were bound to magnetic beads conjugated with Ni-NTA. Binding to the beads and subsequent washing steps were carried out in protein denaturing buffers, which effectively removed host cell proteins from the beads. Disulphide bonds were reduced and thiol groups alkylated. The immobilised proteins were digested with trypsin, followed by MALDI-MS analysis of the tryptic peptides. Figure 15 and Table 9 shows the mass spectrum of tryptic peptides of a 41 kd His₆-tag GAPDH fusion protein. The protein was alkylated with 4-vinylpyridine after reduction with tris(2-carboxyethyl)-phosphine hydrochloride (TCEP-HCl). A phosphine was used instead of thiols in the reduction step, because thiols as dithiothreitol were observed to react with nickel on the magnetic beads. The N-terminal tryptic peptide with the His₆-tag remained on the beads and is not visible in the spectrum of GAPDH. In other experiments, 1% TFA was used to elute peptides, including the His_{6} -tag, from the beads. 62% of the sequence of the fusion protein were confirmed. Many small peptides were not observed because of signal noise below 600 m/z. All peptides with a molecular mass of more than 1,470 were visible. In order to confirm the remaining sequence of this protein, other cleaving enzymes or reagents, like chymotrypsin or cyanogen bromide would have to be used.

The same technique has been used to characterise a 21 kd human calmodulin His₆ fusion protein identified in the hEx1 cDNA library, and a 59 kd human Ikaros 1 (hIk-1, GenBank U40462, ref. 116) His₆ fusion protein. 53% of the sequence of calmodulin was confirmed by the mass spectrum, and all observed peaks over 800 m/z were related to tryptic peptides of the calmodulin fusion protein. The spectrum of the tryptic digest of the hIk-1 fusion protein appeared more complex (data not shown). Many peaks were not assigned to tryptic peptides, presumably because of the high number of 20 cysteines, which were not completely reduced and alkylated. Furthermore, because of the large size of the protein and the high number of tryptic peptides, many small peaks may have been suppressed by large peaks in their vicinity. With 4-vinylpyridine as the thiol alkylating agent, 38% of the sequence were confirmed in the

spectrum. Additional 5% of the sequence were confirmed, when 4-vinylpyridine was replaced by iodacetamide, which showed a higher reactivity under the conditions used.

In summary, by using MALDI-MS to measure the masses of tryptic peptides of recombinant proteins, the identity of the protein can be verified and furthermore the consistence of the observed and the predicted tryptic digestion products can be confirmed for large parts of the protein. For small or medium sized proteins, as calmodulin and GAPDH, more information was obtained than for the large, cysteine-rich hIk-1 His₆ fusion protein. In the calmodulin and the GAPDH spectrum, all major peaks above 800 m/z were assigned to predicted digestion products, whereas with hIk-1 unassigned peaks were observed, and many peptides were missing from the spectrum, presumably because of incomplete tryptic digestion or reduction and alkylation of cysteines, or because they were suppressed by strong peaks in their vicinity.

| aa | calculated | ΔM | sequence |
|----------|-------------------------------------|-------------------|--|
| residues | $\mathbf{M}\mathbf{w}^{\mathrm{a}}$ | (Da) ^b | |
| 239–241 | 474.28 | 0.04 | LWR |
| 61–64 | 488.32 | -0.05 | LVTR |
| 42–47 | 638.28 | -0.33 | SDTMGK |
| 272–278 | 795.42 | -0.07 | LTGMAFR |
| 50–57 | 805.43 | -0.01 | VGVNGFGR |
| 279–292 | 1,473.77 | 0.06 | VPTANVSVVDLTCR |
| 27–41 | 1,542.73 | -0.06 | QSAASSFASPAEPHR |
| 279–292 | 1,578.83 | 0.03 | VPTANVSVVDLT(pyridylethyl-C)R |
| 111–124 | 1,613.90 | 0.00 | LVINGNPITIFQER |
| 190–206 | 1,719.88 | 0.07 | IISNASCTTNCLAPLAK |
| 354–367 | 1,763.80 | -0.02 | LISWYDNEFGYSNR |
| 111–128 | 2,041.11 | -0.02 | LVINGNPITIFQERDPSK ^c |
| 163–183 | 2,213.11 | -0.04 | VIISAPSADAPMFVMGVNHEK |
| 131–151 | 2,277.04 | -0.03 | WGDAGAEYVVESTGVFTTMEK |
| 162–183 | 2,369.21 | -0.08 | RVIISAPSADAPMFVMGVNHEK ^c |
| 207–230 | 2,595.36 | 0.00 | VIHDNFGIVEGLMTTVHAITATQK |
| 72–99 | 3,308.57 | 0.19 | VDIVAINDPFIDLNYMVYMFQYDSTHGK |
| 316–353 | 4,036.90 | 0.31 | GILGYTEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVK |

 Table 9. Measured Peptide Masses from Figure 15 (GAPDH)

^a Smallest monoisomers

^b Calculated minus measured mass from the MALDI spectrum in Figure 15.

^c Incompletely cleaved



Figure 15. MALDI-MS spectrum of a tryptic digest of GAPDH. GAPDH was expressed as a His₆-tag fusion protein and immobilised on Ni-NTA magnetic beads. The protein was reduced with TCEP and alkylated with 4-vinylpydine (4VP). (PE-C: pyridylethyl-cysteine, a.i.: arbitrary intensity units.)